Background: Most international guidelines recommend triple-therapy regimens consisting of a proton pump inhibitor, clarithromycin, and amoxicillin/metronidazole for at least 7days for the eradication of Helicobacter pylori. However, the efficacy of 7-day clarithromycin-based standard triple therapy for H. pylori infection is currently unacceptable in Korea. In this study, we will compare the efficacy and safety of 7-day standard triple therapy, 10-day sequential therapy, and 10-day concomitant therapy for the first-line treatment of H. pylori infection in Korea. Methods/design: In this multicenter, investigator-blinded, randomized trial we are recruiting adult patients with H. pylori infection from 15 hospitals in Korea to determine whether sequential or concomitant treatment is superior to standard triple therapy. Patients are randomly assigned to receive either standard triple therapy (lansoprazole, amoxicillin, and clarithromycin) for 7days, or sequential treatment (lansoprazole and amoxicillin for the first 5days, followed by lansoprazole, clarithromycin, and metronidazole for another 5days) for 10days, or concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole) for 10days. The primary outcome is the rate of H. pylori eradication in the intention-to-treat population. Discussion: The results of this study will be crucial for determining the optimal regimen for the primary treatment of H. pylori infection in Korea. This study will produce vital evidence that will lead to revisions to guidelines concerning first-line treatment regimens for H. pylori infection. Trial registration: Clinical Research Information Service (CRIS), Republic of Korea, KCT0001980. Registered on 25 July 2016.
All Science Journal Classification (ASJC) codes
- Medicine (miscellaneous)
- Pharmacology (medical)